Results 51 to 60 of about 420 (147)
Frontiers in Cellular and Infection Microbiology, 2023 BackgroundTuberculosis (TB) is a rare but potentially devastating complication in hematopoietic stem cell transplantation (HSCT) recipients. Myelosuppression-related antibiotics should be used cautiously in patients with hematological malignancies ...
Junhong Li +9 more
doaj +1 more source
Open Forum Infectious Diseases, 2022 Abstract Background Nocardia is nearly 100% susceptible to linezolid which is one of the first-line agents for all clinical species and isolates reported in the literature. However, adverse reactions related to myelosuppression and monoamine oxidase inhibition have limited linezolid use to some extent.
Ming Wei +5 more
openaire +1 more source
Antibiotics needed to treat multidrug-resistant infections in neonates. [PDF]
, 2022 Infections remain a leading cause of death in neonates. The sparse antibiotic development pipeline and challenges in conducting neonatal research have resulted in few effective antibiotics being adequately studied to treat multidrug-resistant (MDR ...
Agarwal, R +12 more
core +1 more source
Pharmaceuticals, 2022 To develop and verify a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determining contezolid in plasma and cerebrospinal fluid (CSF). Protein precipitation was performed on samples using linezolid as the internal standard.
Guanxuanzi Zhang +4 more
doaj +1 more source
Drug Discoveries & Therapeutics, 2022 Tuberculosis has become a great global public health threat. Compared with drug-susceptible tuberculosis (TB), the treatment regimens for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) involve more severe adverse events and poorer treatment outcomes. Linezolid (LZD) is the first oxazolidinones used for TB.
Min, Yang +5 more
openaire +2 more sources
Clinical outcomes of contezolid in treating complex tuberculosis: real-world evidence from 11 patients. [PDF]
J Thorac DisBACKGROUND: Tuberculosis (TB) remains a major global health challenge, especially among patients with drug intolerance or comorbidities that limit treatment options. Although linezolid (Lzd), an oxazolidinone antibiotic, has demonstrated good efficacy against Mycobacterium tuberculosis (MTB), its long-term use is frequently associated with serious ...
Liu Y, Cui Z, Fu Y, Chan ED, Hu C.
europepmc +2 more sources
Therapy for Mycobacterium kansasii Infection: Beyond 2018 [PDF]
, 2018 The current standard of care therapy for pulmonary Mycobacterium kansasii infection is isoniazid (300 mg/day), rifampin (600 mg/day), and ethambutol (15 mg/kg/day) for 12 months after achieving sputum culture negativity.
Carolyn M. Shoen +3 more
core +1 more source
In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT The in vitro activity of contezolid (MRX-I) against clinical isolates of Mycobacterium tuberculosis was evaluated using a microtiter broth dilution assay. MRX-I was as effective as linezolid (LZD) in vitro . MRX-I and LZD were subsequently studied in
Carolyn, Shoen +3 more
openaire +2 more sources
Accelerating the development of therapeutic strategies for drug-resistant tuberculosis [PDF]
, 2018 Recent progress in the discovery, development and evaluation of new drugs and combination regimens for drug-resistant tuberculosis through greater collaboration between industry, donors and academia provides renewed hope for overcoming the challenges in ...
Tiberi, S, Vjecha, MJ, Zumla, A
core +1 more source
, 2022 This book focuses on various aspects and applications of drug repurposing, the understanding of which is important for treating diseases. Due to the high costs and time associated with the new drug discovery process, the inclination toward drug ...
core +1 more source